ArticleScientific reports2025
Surgery versus chemoradiotherapy in patients with stage T1bN0M0 esophageal cancer: a retrospective cohort study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To compare survival outcomes between surgery and chemoradiotherapy in patients with stage T1bN0M0 esophageal cancer. Stage T1bN0M0 esophageal cancer patients treated with either surgery or chemoradiotherapy were extracted from the Surveillance, Epidemiology, and End Results database between 2000 and 2020. Included patients were divided into two groups: surgery and chemoradiotherapy. Cancer-specific survival (CSS) and overall survival (OS) were compared between the two groups. Among the 515 patients included in the study, 55 (10.7%) underwent chemoradiotherapy and 460 (89.3%) received surgery. Surgery showed better 5-year CSS (73.2% vs. 31.0%; hazard ratio [HR] = 0.27, 95% confidence interval [CI] 0.19-0.39; P < 0.001) and OS (60.0% vs. 21.5%; HR = 0.35, 95% CI 0.25-0.48; P < 0.001) compared to chemoradiotherapy. Subgroup analysis indicated that surgery remained associated with superior 5-year CSS (61.3% vs. 40.6%; HR = 0.51, 95% CI 0.26-0.99; P = 0.049) and OS (48.9% vs. 23.8%; HR = 0.52, 95% CI 0.29-0.91; P = 0.021) compared to chemoradiotherapy in squamous cell carcinoma patients. Similarly, surgery showed better 5-year CSS (76.0% vs. 27.1%; HR = 0.22, 95% CI 0.14-0.34; P < 0.001) and OS (62.7% vs. 20.6%; HR = 0.31, 95% CI 0.21-0.46; P < 0.001) compared to chemoradiotherapy in adenocarcinoma patients. Surgery is associated with superior survival outcomes compared to chemoradiotherapy in stage T1bN0M0 esophageal cancer and should be considered the preferred treatment for eligible patients, particularly in settings where consistent follow-up and salvage therapy may be limited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.